Wuhan Keqian Biology Co.,Ltd (SHSE: 688526)
Health Care · Pharmaceuticals · CN
CN¥13.09
+0.31% today · -27.7% 1Y
Wuhan Keqian Biology Co.,Ltd (SHSE: 688526) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $903.35M and employs 950 people.
Over the last twelve months the share price has lost 27.7%, trading between 11.65 and 20.39.
Tweenvest scores Wuhan Keqian Biology Co.,Ltd across four factors: quality 75/100, value 81/100, growth 35/100, dividend 44/100. Its strongest factor is value.
688526 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $903.35M
- Revenue (TTM)
- $135.14M
- P/E
- 15.59
- EPS
- 0.84
- Dividend yield
- 4.89%
- Beta (5Y)
- 0.34
- 52-week high
- CN¥20.39
- 52-week low
- CN¥11.65
- Avg volume (3M)
- —
- Shares outstanding
- 463.92M
- Employees
- 950
- Next earnings
- —
About Wuhan Keqian Biology Co.,Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.
- ISIN
- CNE1000042Q8
- Founded
- 2001
- Listed since
- Sep 22, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.36 | +0.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.50 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.